Could This Be IT? Epicutaneous, Sublingual, and Subcutaneous Immunotherapy for the Treatment of Food Allergies

被引：10

作者：

Baker, Mary Grace ^{[1
]}

Wang, Julie ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Pediat Allergy & Immunol, One Gustave L Levy Pl,Box 1198, New York, NY 10029 USA

来源：

CURRENT ALLERGY AND ASTHMA REPORTS | 2019年 / 19卷 / 11期

关键词：

Food allergy; Food hypersensitivity; Anaphylaxis; Peanut hypersensitivity; Nut and Peanut hypersensitivity; ARA H 2; REGULATORY T-CELLS; QUALITY-OF-LIFE; PEANUT ALLERGY; ORAL IMMUNOTHERAPY; DOUBLE-BLIND; HISTORICAL-PERSPECTIVE; DELIVERY-SYSTEM; INTACT SKIN; SAFETY;

D O I：

10.1007/s11882-019-0885-z

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Purpose of Review Over the last decade, there has been a spark in innovation in the development of therapies for food allergy. Herein, we describe the background and recent advances for food-specific immunotherapies including epicutaneous (EPIT), sublingual (SLIT), and subcutaneous (SCIT). Recent Findings Studies have progressed most quickly for the treatment of peanut allergy. Data from the phase 3 EPIT trial add to the accumulating evidence that this will be a viable therapy for peanut allergy. Studies for SLIT and SCIT remain in earlier phases with promising results. Summary This is an exciting era for the treatment of food allergy. Multiple therapies are under investigation, each with their own potential advantages. Specific strengths and limitations of each of these therapies may provide an opportunity to personalize the choice of therapy for individual patients.

引用

页数：12

共 77 条

[1] Immunological mechanisms of sublingual immunotherapy [J].

Akdis, C. A. ;

Barlan, I. B. ;

Bahceciler, N. ;

Akdis, M. .

ALLERGY, 2006, 61 :11-14

[2]

[Anonymous], 2016, Finding a path to safety in food allergy: assessment of the Global Burden, causes, prevention, management, and public policy, DOI DOI 10.17226/23658

[3]

[Anonymous], PLOS MED

[4]

Asthme dorigine VRP, 1921, Boll Soc Med Ho^p Paris, V45, P1251

[5] Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy [J].